Lidocaine — research review 2

...and while lidocaine can be a vital tool for acute pain relief, especially for conditions like neuropathic pain via patches or IV, the long-term picture regarding aging and all-cause mortality is nuanced.

Absolutely. It’s a sodium channel blocker, working as a local anesthetic. For conditions like painful diabetic neuropathy, we know unrelieved pain itself can accelerate biological aging, as evidenced by findings in GeroScience 2025 showing accelerated epigenetic aging and telomere shortening in those with painful neuropathy versus painless.

So, there’s a clear benefit in pain management. But when we look at lidocaine specifically, especially with chronic, widespread use, research on its direct impact on all-cause mortality and long-term harms is still evolving.

Right. We're not seeing robust, long-term studies definitively linking chronic lidocaine use to improved or worsened all-cause mortality in the general population. The focus has been on short-term efficacy and safety.

Serious long-term harms like dependence, falls, sedation, or cognitive issues are certainly concerns with other pain medications, but direct, independent links to lidocaine and increased all-cause mortality or accelerated biological aging beyond its immediate effects haven't been clearly established in large-scale human trials.

What’s genuinely beneficial is its targeted use under supervision for specific pain conditions where the pain itself is a significant health detractor. The uncertainty lies in how chronic, systemic exposure might influence broader aging pathways or long-term survival, which remains largely unproven. It's about weighing known benefits against potential, though unconfirmed, long-term risks.